1. Preclinical immunogenicity testing using anti-drug antibody analysis of GX-G3, Fc-fused recombinant human granulocyte colony-stimulating factor, in rat and monkey models
- Author
-
Kyung Jin Jung, Sang Kyum Kim, Sang In Yang, Yun Jung Kim, Mi Sun Byun, Yu Ri Choi, Eun Mi Koh, Chi Hun Song, Eun-Jeong Jeon, and Kyunghwa Hwang
- Subjects
0301 basic medicine ,Male ,Science ,Injections, Subcutaneous ,Recombinant Fusion Proteins ,Drug Evaluation, Preclinical ,Gene Expression ,Enzyme-Linked Immunosorbent Assay ,Granulocyte ,Neutropenia ,Pharmacology ,Article ,Antibodies ,law.invention ,Rats, Sprague-Dawley ,03 medical and health sciences ,0302 clinical medicine ,law ,Granulocyte Colony-Stimulating Factor ,Antibody generation ,Toxicokinetics ,Medicine ,Animals ,Humans ,Immunologic Factors ,Immunological disorders ,Multidisciplinary ,biology ,business.industry ,Immunogenicity ,Myeloid leukemia ,medicine.disease ,Granulocyte colony-stimulating factor ,Immunoglobulin Fc Fragments ,Rats ,Macaca fascicularis ,030104 developmental biology ,medicine.anatomical_structure ,Risk factors ,Recombinant DNA ,biology.protein ,Female ,Antibody ,business ,030215 immunology - Abstract
Human granulocyte colony-stimulating factor (G-CSF, this study used Fc-fused recombinant G-CSF; GX-G3) is an important glycoprotein that stimulates the proliferation of granulocytes and white blood cells. Thus, G-CSF treatment has been considered as a crucial regimen to accelerate recovery from chemotherapy-induced neutropenia in cancer patients suffering from non-myeloid malignancy or acute myeloid leukemia. Despite the therapeutic advantages of G-CSF treatment, an assessment of its immunogenicity must be performed to determine whether the production of anti-G-CSF antibodies causes immune-related disorders. We optimized and validated analytical tools by adopting validation parameters for immunogenicity assessment. Using these validated tools, we analyzed serum samples from rats and monkeys injected subcutaneously with GX-G3 (1, 3 or 10 mg/kg once a week for 4 weeks followed by a 4-week recovery period) to determine immunogenicity response and toxicokinetic parameters with serum concentration of GX-G3. Several rats and monkeys were determined to be positive for anti-GX-G3 antibodies. Moreover, the immunogenicity response of GX-G3 was lower in monkeys than in rats, which was relevant to show less inhibition of toxicokinetic profiles in monkeys, at least 1 mg/kg administrated group, compared to rats. These results suggested the establishment and validation for analyzing anti-GX-G3 antibodies and measurement of serum levels of GX-G3 and anti-GX-G3 antibodies, which was related with toxicokinetic profiles. Taken together, this study provides immunogenicity assessment which is closely implicated with toxicokinetic study of GX-G3 in 4-week repeated administrated toxicological studies.
- Published
- 2021